Evidence map›Paper›PMID 40214152›Full record

ArticleImmunity, inflammation and disease2025

RETRACTION: LncRNA TUG1 Relieves Renal Mesangial Cell Injury by Modulating the miR-153-3p/Bcl-2 Axis in Lupus Nephritis.

Abstract readRetraction Notice
In one paragraph

Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

retractionL. Liu, Y. Zhang and L. Zhong, "LncRNA TUG1 Relieves Renal Mesangial Cell Injury by Modulating the miR-153-3p/Bcl-2 Axis in Lupus Nephritis," Immunity, Inflammation and Disease 11, no. 4 (2023): e811, https://doi.org/10.1002/iid3.811. The above article, published online on 12 April 2023 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Marc Veldhoen; and John Wiley & Sons Ltd. The retraction has been agreed upon following an investigation into concerns raised by a third party. The investigation revealed that the LPS+miR-153-3p inhibitor flow cytometry plot presented in Figure 6B has been found duplicated in another article by a different author group representing different scientific conditions. The authors provided an explanation and some data but this was not deemed sufficient. The editors have lost confidence in the data presented and consider the conclusions to be compromised. The authors disagree with the retraction.

Identifiers

PMID40214152
PMCPMC11987038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.